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Dear Editor, 
Hypercalcemia of malignancy (HCM) is a paraneoplastic syndrome estimated to occur in 
up to 30 % of cancer patients. The two major types of HCM differ in their pathophysiology: 
humoral, whereby tumors secrete parathyroid hormone-related protein that promotes increased 
osteoclast activity and bone resorption with subsequent release of calcium, and secondly, oste-
olytic HCM due to excessive calcium release from bone secondary to malignant invasion of the 
bone marrow. Humoral HCM is associated with renal, ovarian, breast and squamous cell carci-
nomas whereas osteolytic HCM is often observed in malignancies with bone metastasis, in ad-
dition to breast cancer and myeloma (Feldenzer and Sarno, 2018). 
The diagnostic hallmark of the myeloproliferative neoplasm (MPN) of chronic myeloid leu-
kemia (CML) is the Philadelphia (Ph) chromosome resulting in the BCR-ABL1 fusion gene, 
whereas the most commonly acquired genetic abnormality in the Ph-negative MPN of polycy-
themia vera, essential thrombocythemia and primary myelofibrosis is the JAK2 V617F muta-
tion. In addition to these molecular features, additional clinico-pathological criteria are neces-
sary for the diagnosis and classification of these MPN (Arber et al., 2016). Despite these crite-
ria, hypercalcemia in the absence of other clinical or laboratory features of an MPN has become 
a periodic, if infrequent prompt for molecular testing of the BCR-ABL1 fusion and/or the JAK2 
V617F. 
In order to address the clinical and laboratory value of such requests, a retrospective audit 
was performed on all diagnostic BCR-ABL1 and JAK2 V617F requests received at a molecular 
diagnostics center for hematological malignancies from January 2006 to June 2019 inclusive. 
Of 20,086 and 9,570 diagnostic requests for the JAK2 V617F mutation and BCR-ABL1 fusion 
respectively, 59 requests (0.2 %) were received for investigation of either JAK2 V617F (n=35), 
BCR-ABL1 (n=12) or both (n=12), with the sole clinical details provided of hypercalcemia. The 
median age was 63 years and comprised 34 males and 25 females. Using standardised assays, 
the JAK2 V617F mutation or BCR-ABL1 fusion were not detected in any of the 59 patients. 
Which patients to screen for MPN-associated rearrangements and mutations requires scru-
tiny in order to optimise laboratory resources, however the number of requests with hypercalce-
mia did not adversely affect laboratory workload. Acknowledging that HCM has been previ-
ously reported in rare instances of CML and MPN (Khoury et al., 2012; Toro-Tobón et al., 
2017), the rationale for reflexive screening of the BCR-ABL1 and JAK2 V617F rearrangements 
in patients presenting with hypercalcaemia without other evidence of an MPN is unfounded.  
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